For research use only. Not for therapeutic Use.
Metarrestin (CAT: I018156), known as ML246, represents a pioneering compound in cancer research and therapeutic development. As a first-in-class, orally active inhibitor, it specifically targets the perinucleolar compartment, disrupting nucleolar structure and inhibiting RNA polymerase I (Pol I) transcription. Metarrestin’s unique mechanism involves interaction with the translation elongation factor eEF1A2. This disruption of nucleolar function contributes to its potential to block metastatic development and extend survival in mouse cancer models.
| Catalog Number | I018156 |
| CAS Number | 1443414-10-5 |
| Molecular Formula | C₃₁H₃₀N₄O |
| Purity | ≥95% |
| Reference | [1]. Vilimas T, et al. Pharmacokinetic evaluation of the perinucleolar compartment disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. Cancer Chemother Pharmacol. 2018 Dec;82(6):1067-1080.<br>[2]. Frankowski KJ, et al. Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Sci Transl Med. 2018 May 16;10(441). |
